A number of other equities analysts also recently issued reports on HALO. Zacks Investment Research raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating and set a $37.00 price target for the company in a report on Monday, March 14th. Piper Sandler reduced their price objective on Halozyme Therapeutics from $43.00 to $42.00 in a research note on Wednesday, February 23rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $47.83.
NASDAQ HALO opened at $41.74 on Tuesday. The company has a market cap of $5.75 billion, a P/E ratio of 15.18 and a beta of 1.32. The company has a debt-to-equity ratio of 4.00, a current ratio of 7.91 and a quick ratio of 7.45. The stock has a 50-day moving average of $37.28 and a two-hundred day moving average of $36.91. Halozyme Therapeutics has a 1-year low of $31.36 and a 1-year high of $51.57.
A number of hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors grew its holdings in Halozyme Therapeutics by 12.1% during the third quarter. Captrust Financial Advisors now owns 2,898 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 313 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in shares of Halozyme Therapeutics by 0.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 48,612 shares of the biopharmaceutical company’s stock valued at $1,955,000 after acquiring an additional 337 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 4.9% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 9,664 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 452 shares during the last quarter. Securian Asset Management Inc. boosted its stake in shares of Halozyme Therapeutics by 3.8% during the third quarter. Securian Asset Management Inc. now owns 12,764 shares of the biopharmaceutical company’s stock valued at $519,000 after acquiring an additional 464 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Halozyme Therapeutics by 4.7% during the fourth quarter. Fifth Third Bancorp now owns 11,793 shares of the biopharmaceutical company’s stock valued at $474,000 after acquiring an additional 534 shares during the last quarter. 90.21% of the stock is currently owned by hedge funds and other institutional investors.
About Halozyme Therapeutics (Get Rating)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.